Results 171 to 180 of about 918,364 (316)

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Demographic Variation in Prenatal Care Coordination Receipt and Resulting Birth Outcomes: Evidence From the Wisconsin Medicaid Population. [PDF]

J Public Health Manag Pract
Mallinson DC, Green TL, Gillespie KH.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Developing a Core Outcome Measurement Set for Adult ICU Patients, the CoreMS-ICU-A Protocol. [PDF]

Acta Anaesthesiol Scand
Kjær MN, Bruun CRL, Mortensen CB, Schandl A, Haines K, Hofsø K, Blokzijl F, Granholm A, Møller MH, Tøgern A, Rasmussen BS, Poulsen LM, Strøm T, Laerkner E, Brøchner AC, Haberlandt T, Bunzel AG, Herløv LS, Holm A, Sivapalan P, Estrup S, Cronhjort M, Laake JH, Pfortmueller CA, Ostermann M, Cole JM, Wise MP, Wludarczyk A, Szczeklik W, Jovaiša T, Cecconi M, Sigurdsson MI, Nalos M, Hästbacka J, Mäkinen M, Dye J, Hammond N, Litton E, Keus F, Myatra SN, Vijayaraghavan BKT, Yadav K, Venkatesh B, Egerod I, Larsen RF, Needham DM, Rose L, Connolly B, Spies C, Hodgson C, Munblit D, Gorst S, Perner A, Collet MO.   +53 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Endotracheal Tube Repositioning Frequency for Preventing Oral Mucosal Pressure Injuries in Intensive Care Units: A Randomised Controlled Trial Study Protocol. [PDF]

Nurs Crit Care
Ozdemır E, Korkmaz F, Derelı N.
europepmc   +1 more source

Metodologia de avaliação do trabalho na atenção primária à saúde

Cadernos de Saúde Pública
No presente trabalho, realiza-se um estudo de caso, no qual se analisa o processo de avaliação de ações assistenciais em uma unidade básica de saúde, no sentido de contribuir para o desenvolvimento de metodologias de avaliação do trabalho assistencial e ...
Arnaldo Sala, Maria Ines Baptistella Nemes, Diane Dede Cohen   +2 more
doaj  

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Evaluation of a novel role proposal for the use of a physiotherapist navigator in an acute cancer care setting in Ontario: Protocol for a pilot randomized controlled trial. [PDF]

PLoS One
Edward H, Macedo L, Wojkowski S, Mukherjee SD, Smith-Turchyn J.   +4 more
europepmc   +1 more source

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

FEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda, Satoru Sugimoto, Chiharu Cho, Madoka Konishi, Nozomi Inoue, Satoshi Miyagaki, Yasuhiro Kawabe, Takuro Okamura, Masahide Hamaguchi, Hisakazu Nakajima, Michiaki Fukui, Masakazu Shinohara, Tomoko Iehara   +12 more
wiley   +1 more source